Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05353400
Other study ID # IRB00083499
Secondary ID V13-30-2022
Status Terminated
Phase N/A
First received
Last updated
Start date June 29, 2022
Est. completion date April 6, 2023

Study information

Verified date April 2023
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to investigate whether patients who self-remove their indwelling transurethral catheters on POD 1 have similar rates of postoperative catheter reinsertion for urinary retention (within the first 7 days after surgery) compared with those who undergo catheter self-removal on POD 3.


Description:

Studies estimate the rate of post-operative urinary retention (POUR) after pelvic reconstructive surgery to be between 2.5-43% in all patients1. Consequently, patients undergoing pelvic reconstructive surgery will commonly undergo an assessment of voiding function prior to discharge. Patients who do not successfully complete a voiding trial (VT) are typically discharged from the hospital with a transurethral indwelling catheter. The preferred length of time the catheter remains in place postoperatively, however, varies widely (1 to 7 days) amongst pelvic reconstructive surgeons2-4. Over the past few years, Enhanced Recovery After Surgery (ERAS) protocols have been adopted for patients undergoing reconstructive vaginal and minimally invasive (laparoscopic or robotic) surgery with increased focus on patient centered outcomes5. The benefits of ERAS in pelvic reconstructive surgery often allow for patients to be discharged home from the hospital the same day of their surgery. Unfortunately, same day discharge is associated with higher rates of postoperative voiding dysfunction and subsequent discharge home with a urinary catheter, with an incidence reported as high as 33.9-36%2,6. This increased rate of postoperative urinary retention has been reflected in our patient population. Prior to the implementation of ERAS in our pelvic reconstructive surgery division at Atrium Health, the rate of discharge home with a urinary catheter after failed VT on postoperative day (POD) 1 was 28%. With the implementation of an ERAS protocol and same day discharge (POD 0), the rate climbed to 43%7. Consequently, a higher percentage of postoperative patients have required a second VT prior to catheter discontinuation. This has necessitated additional clinical visits with a nurse or other provider, further stretching our clinical staff and obligating patients to make an additional trip to the clinic for a repeat postoperative VT. Recent evidence supports the safety and improved patient experience in patients who self-discontinue a transurethral urinary catheter. In the study by Shatkin-Margolis et al., patients who had undergone pelvic reconstructive surgery were randomized to either self- discontinuation or in office discontinuation overseen by medical personnel one week after surgery8. This study found that self-discontinuation of transurethral catheter was non-inferior to office-based discontinuation following pelvic reconstructive surgery. Additionally, the authors found that self-discontinuation resulted in fewer patient encounters and improved patient experience. Given this supportive evidence of safe catheter self-discontinuation and our practice's desire to improve patient satisfaction while decreasing clinical burden, we have adopted a practice where the patient self-removes their urinary catheter on the same day that a typical in-office VT would occur (POD 3). During preoperative counseling visits, our patients receive structured handouts with pictorial and descriptive language explaining how to safely self-remove a transurethral catheter (Figure 1). If VT failure should occur, the post anesthesia care unit (PACU) nursing staff review the instructions once again with the patient and the patient's support person(s) prior to discharge. Patients are told to call the office with any symptoms or concerns. Additionally, a nurse from our practice follows up with the patient via telephone on POD 1. Patient experience following surgery is an important patient centered outcome. Unfortunately, being discharged home with an indwelling transurethral catheter for any amount of time is often perceived by patients as a postoperative complication and is a source of dissatisfaction in patients undergoing pelvic reconstructive surgery9-10. Therefore, decreasing the dissatisfaction surrounding postoperative catheter use improves the patient experience. Several studies have evaluated early postoperative catheter discontinuation after pelvic reconstructive surgery in an effort to limit the length of time that a catheter is in place. In a randomized controlled trial of immediate versus POD1 catheter removal in patients undergoing minimally invasive pelvic reconstructive surgery by Vallabh-Patel et al. the rate of POUR on POD 0 was 31%; however, the rate on POD 1 was 4.5%2. Similar low rates of POUR were noted in a prospective cohort trial performed by Botros et al. which evaluated the effects of a mid-urethral sling at the time of robotic sacrocolpopexy and noted a POD 1 retention rate of 1% in this patient population11. Finally, in a retrospective cohort study incorporating both laparoscopic and vaginal pelvic reconstructive surgery performed by El Hiraki et al., the rate of failed VT within 23 hours of surgery was 11.1% for minimally invasive group and 34% for the vaginal surgery group12. This limited body of evidence suggests that a voiding trial as early as postoperative day 1 seems to yield a voiding trial pass rate of 1-34% in pelvic reconstructive surgery patients. Our group aims to optimize urinary catheter management for both the patient and the clinical staff in the postoperative period when patients are discharged on the same day of their surgery with a transurethral urinary catheter. We are proposing a non-inferiority trial comparing at home POD 1 catheter removal with at home POD 3 catheter removal (our current standard of practice).


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date April 6, 2023
Est. primary completion date April 6, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - English speaking Age 18+ Undergoing pelvic reconstructive surgery with ERAS protocol Incomplete bladder emptying after same day VT in PACU (as defined by an ultrasound or straight catheter post void residual of greater than 50% the total instilled volume within 10 minutes following a void postoperatively) Able to complete a telephone appointment on either postoperative day 1 or 3 Exclusion Criteria: - Active urinary tract infection, defined by CDC criteria Patients undergoing pelvic reconstructive surgery where ERAS protocol is not utilized (examples: isolated Labiaplasty, chemodenervation with onabotulinum toxin A, urethral bulking, mid-urethral sling, sacral neuromodulation) Contraindication to ERAS protocol and/or its medications Elevated pre-op PVR greater than 200mL (on urodynamic testing or uroflow or straight catheter sample, that remains elevated after prolapse is reduced) Limited manual dexterity (limiting self-removal of catheter) Intra-op cystotomy or urinary tract injury Planned long term catheterization (e.g., fistula repair, urethral diverticulum) Planned hospital admission or patients who are not discharged from hospital the same day of their surgery Pregnancy Dependent on catheterization to void preoperatively Patients who request clean intermittent catheterization (CIC) after immediate failed VT Neurological conditions that affect voiding function (examples: spinal cord lesions, multiple sclerosis, Parkinson's disease, past stroke history with residual neurologic deficits) Concomitant surgical procedure by another service Conversion to open surgery Patients discharged to nursing home or rehabilitation care facility

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Early urinary catheter removal
Early catheter removal
Urinary catheter removal on POD 3
Catheter removal on POD 3

Locations

Country Name City State
United States Atrium Health Charlotte North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients requiring re-insertion of a transurethral urinary catheter Percentage of patients with urinary retention requiring re-insertion of a transurethral urinary catheter or needing to do self catheterization within one week of surgery after catheter self-discontinuation on either POD 1 or POD 3 following pelvic reconstructive surgery utilizing ERAS protocol. 7 days
Secondary Short Term Catheter Burden Questionnaire Postoperative patient satisfaction using validated questionnaire-Short Term Catheter Burden Questionnaire (STCBQ)13 recorded on day of catheter removal.
Total scale score from 5 to 30. Higher scores indicate greater embarrassment/bother.
7 days
Secondary Urinary Force of stream Urinary Force of stream (FOS) reported in millimeters (mm) on visual analog scale (VAS) for first void after catheter removal 14-15 (Figure 3) recorded on day of catheter removal 7 days
Secondary Urinary tract infection rate Urinary tract infection (UTI) rates-first 30 days after surgery defined by the CDC criteria
This will be reported as an absolute number and calculated and reported as a percentage of the total number of patients who had a UTI/ total number of patients in the study.
30 days
Secondary Number of patient phone calls Number of patient phone calls to triage nursing or clinic in first 7 days following surgery 7 days
Secondary Number of visits Number of visits (Emergency room/clinic/post anesthesia care unit (PACU), other) for catheter reinsertion within 30 days of surgery 30 days
Secondary Readmission rates 30-day readmission rates 30 days
Secondary Prolonged catheterization Need for prolonged catheterization or clean intermittent self catheterization (CIC) for greater than 7 days
This will be reported as an absolute number and calculated and reported as a percentage of the total number of patients who required greater than 7 days of catheterization/ total number of patients in the study.
30 days
See also
  Status Clinical Trial Phase
Recruiting NCT05794503 - Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex Early Phase 1
Active, not recruiting NCT04010656 - Optimization of Spontaneous Postoperative Trial of Void Among Women N/A
Recruiting NCT04597372 - Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery Phase 2
Not yet recruiting NCT06344884 - Early Patient Removal of Urinary Catheters After Urogynecologic Surgery N/A
Recruiting NCT04707001 - Urinary Retention After Arthroplasty N/A
Recruiting NCT06241703 - Effect of ICCAUT Strategy on Postoperative Urinary Dysfunction After Radical Rectal Cancer Surgery N/A
Completed NCT03818321 - Urinary Track Infection Prevention After Urogynecological Surgery Phase 2
Not yet recruiting NCT06262048 - Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial Phase 2
Recruiting NCT05020613 - Early and Late Removal of the Urinary Catheter After Rectum Resection N/A
Completed NCT03071211 - Catheter Management After Pelvic Reconstructive Surgery N/A
Recruiting NCT05249192 - Immediate Versus Early (24-hours) Urinary Catheter Removal After Elective Minimally Invasive Colonic Resection N/A
Completed NCT04783012 - Patient Removal of Catheters After Urogynecologic Surgery N/A
Recruiting NCT04465578 - Incidence of Short-term Urinary Retention After Fascial Retropubic Sling: Prospective and Randomized Analysis. N/A
Completed NCT03065075 - Effect of Phenazopyridine on Prolapse Surgery Voiding Trials Phase 3
Completed NCT05108506 - Strict Need to Void After Same-day Discharge, Non-urogynecologic, Minimally Invasive Hysterectomy N/A
Enrolling by invitation NCT05887375 - Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery Phase 4
Recruiting NCT03808155 - Prevention of Postoperative Urinary Retention With Treatment of Tamsulosin 5 Days Prior to Lower Limb Arthroplasty Phase 4
Completed NCT04859660 - Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy Phase 2